SMPD3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL127192	0.57	17/20
Hydrochloric Acid (SCHEMBL1735170)	0.71	16/20
SCHEMBL1826556	0.62	16/20
SCHEMBL129183	0.61	15/20
SCHEMBL1825810	0.64	14/20
SCHEMBL860108	0.50	14/20
SCHEMBL1827762	0.50	14/20
SCHEMBL2178745	0.47	14/20
SCHEMBL2178752	0.47	14/20
SCHEMBL1441141	0.41	14/20
SCHEMBL1820733	0.66	13/20
SCHEMBL2238233	0.48	13/20
SCHEMBL861193	0.51	12/20
SCHEMBL861194	0.51	12/20
SCHEMBL1827861	0.63	11/20
SCHEMBL244059	0.80	10/20
SCHEMBL175592	0.75	10/20
SCHEMBL1825191	0.66	10/20
SCHEMBL1826311	0.49	10/20
SCHEMBL1443512	0.62	9/20

Clinical trials — most relevant to SMPD3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Ambroxol as a Treatment for Parkinson's Disease Dementia	PHASE2	UNKNOWN
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients	PHASE1	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children	nan	NOT_YET_RECRUITING
Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease	nan	NOT_YET_RECRUITING
Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency	nan	NOT_YET_RECRUITING
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
Biomarkers Of Lung InVolvement In ASMD	nan	UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)	nan	RECRUITING
Precision Medicine for Sng/Pain Control	nan	COMPLETED
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)	nan	APPROVED_FOR_MARKETING
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Intralumenal Effects on Cholesterol Absorption/Synthesis	nan	COMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders	nan	UNKNOWN
A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Diagnostic Creteria of Acid Sphingomyelinase Deficiency (ASMD)	nan	ACTIVE_NOT_RECRUITING
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Canadian Fabry Disease Initiative (CFDI) National Registry	nan	RECRUITING
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a SMPD3 binder may also engage these)

Protein	Name	Similarity
Q9JJY3	—	1.000	Q9JJY3 →
O35049	—	1.000	O35049 →
F1QG30	—	0.980	F1QG30 →
O00562	—	0.979	O00562 →
O35954	—	0.979	O35954 →
Q2I6J1	—	0.978	Q2I6J1 →
P0CI65	—	0.976	P0CI65 →
Q99MQ3	—	0.976	Q99MQ3 →
O88943	—	0.976	O88943 →
Q5R7X0	—	0.976	Q5R7X0 →
Q17QP1	—	0.976	Q17QP1 →
A5D794	—	0.976	A5D794 →
Q3B7T1	—	0.975	Q3B7T1 →
Q9JK97	—	0.975	Q9JK97 →
Q6P5D8	—	0.975	Q6P5D8 →
B5DFG1	—	0.975	B5DFG1 →
Q62141	—	0.975	Q62141 →
Q9BZ72	—	0.975	Q9BZ72 →
Q2I6J0	—	0.975	Q2I6J0 →
E9PUQ8	—	0.975	E9PUQ8 →
FTO	Alpha-ketoglutarate-dependent dioxygenase FTO	0.975	landscape →
Q5ZI40	—	0.975	Q5ZI40 →
Q5JCS6	—	0.975	Q5JCS6 →
Q6EE22	—	0.974	Q6EE22 →
Q6P1Y8	—	0.974	Q6P1Y8 →
Q8C0M0	—	0.974	Q8C0M0 →
A0A8I3NFE2	—	0.974	A0A8I3NFE2 →
A1A4J7	—	0.974	A1A4J7 →
Q93ZS1	—	0.974	Q93ZS1 →
Q8CF97	—	0.974	Q8CF97 →